Tags

Type your tag names separated by a space and hit enter

Management of dyslipidemia in diabetes.
Cardiol Rev. 2006 May-Jun; 14(3):125-35.CR

Abstract

Diabetes is associated with a high risk of cardiovascular disease. The management of dyslipidemia, a well-recognized and modifiable risk factor among patients with type 2 diabetes, is an important element in the multifactorial approach to prevent coronary heart disease. Diabetic dyslipidemia typically consists of elevated triglyceride, low high-density lipoprotein cholesterol (HDL-C), and the predominance of small dense low-density lipoprotein (LDL) particles. LDL cholesterol (LDL-C) levels in patients with diabetes are similar to those found in the rest of the population. During the past few years, clinical trials have provided evidence that lipid-lowering therapy has a similar beneficial effect on cardiovascular outcomes in diabetic and nondiabetic individuals. According to current guidelines, the primary lipid target is an LDL-C <100 mg/dL (<70 mg/dL in very high-risk patients) and, to this end, statins are the agents of choice. The appropriate management of dyslipidemia in patients with diabetes, particularly in individuals with low LDL-C, remains controversial. To achieve lipid targets, attention should be directed first toward nonpharmacologic therapeutic interventions to control dyslipidemia, such as diet, exercise, smoking cessation, weight loss, and glycemic control. Statin therapy is recommended for most subjects but, frequently, a combination of lipid-lowering agents is required. A number of combinations are possible, and several factors should be considered to improve the safety of this strategy.

Authors+Show Affiliations

University of Miami School of Medicine, Miami, Florida, USA. msolano@med.miami.eduNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16628021

Citation

Solano, Maria P., and Ronald B. Goldberg. "Management of Dyslipidemia in Diabetes." Cardiology in Review, vol. 14, no. 3, 2006, pp. 125-35.
Solano MP, Goldberg RB. Management of dyslipidemia in diabetes. Cardiol Rev. 2006;14(3):125-35.
Solano, M. P., & Goldberg, R. B. (2006). Management of dyslipidemia in diabetes. Cardiology in Review, 14(3), 125-35.
Solano MP, Goldberg RB. Management of Dyslipidemia in Diabetes. Cardiol Rev. 2006 May-Jun;14(3):125-35. PubMed PMID: 16628021.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Management of dyslipidemia in diabetes. AU - Solano,Maria P, AU - Goldberg,Ronald B, PY - 2006/4/22/pubmed PY - 2006/9/29/medline PY - 2006/4/22/entrez SP - 125 EP - 35 JF - Cardiology in review JO - Cardiol Rev VL - 14 IS - 3 N2 - Diabetes is associated with a high risk of cardiovascular disease. The management of dyslipidemia, a well-recognized and modifiable risk factor among patients with type 2 diabetes, is an important element in the multifactorial approach to prevent coronary heart disease. Diabetic dyslipidemia typically consists of elevated triglyceride, low high-density lipoprotein cholesterol (HDL-C), and the predominance of small dense low-density lipoprotein (LDL) particles. LDL cholesterol (LDL-C) levels in patients with diabetes are similar to those found in the rest of the population. During the past few years, clinical trials have provided evidence that lipid-lowering therapy has a similar beneficial effect on cardiovascular outcomes in diabetic and nondiabetic individuals. According to current guidelines, the primary lipid target is an LDL-C <100 mg/dL (<70 mg/dL in very high-risk patients) and, to this end, statins are the agents of choice. The appropriate management of dyslipidemia in patients with diabetes, particularly in individuals with low LDL-C, remains controversial. To achieve lipid targets, attention should be directed first toward nonpharmacologic therapeutic interventions to control dyslipidemia, such as diet, exercise, smoking cessation, weight loss, and glycemic control. Statin therapy is recommended for most subjects but, frequently, a combination of lipid-lowering agents is required. A number of combinations are possible, and several factors should be considered to improve the safety of this strategy. SN - 1061-5377 UR - https://www.unboundmedicine.com/medline/citation/16628021/Management_of_dyslipidemia_in_diabetes_ DB - PRIME DP - Unbound Medicine ER -